These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31940946)

  • 1. Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.
    Khurana N; Chandra PK; Kim H; Abdel-Mageed AB; Mondal D; Sikka SC
    Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31940946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huaier Extract Inhibits Prostate Cancer Growth
    Liu Z; Liu C; Yan K; Liu J; Fang Z; Fan Y
    Front Oncol; 2021; 11():615568. PubMed ID: 33708629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer.
    Zheng Z; Li J; Liu Y; Shi Z; Xuan Z; Yang K; Xu C; Bai Y; Fu M; Xiao Q; Sun H; Shao C
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
    Regufe da Mota S; Bailey S; Strivens RA; Hayden AL; Douglas LR; Duriez PJ; Borrello MT; Benelkebir H; Ganesan A; Packham G; Crabb SJ
    Cancer Cell Int; 2018; 18():71. PubMed ID: 29760584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer.
    Park HK; Lim SD; Kwon GY
    Scand J Urol; 2019 Dec; 53(6):365-371. PubMed ID: 31809622
    [No Abstract]   [Full Text] [Related]  

  • 9. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
    Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer.
    Sekine Y; Nakayama H; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Oncol Lett; 2021 Dec; 22(6):831. PubMed ID: 34691258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer.
    Case TC; Merkel A; Ramirez-Solano M; Liu Q; Sterling JA; Jin R
    Transl Oncol; 2021 Nov; 14(11):101213. PubMed ID: 34461557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
    Guzman J; Weigelt K; Neumann A; Tripal P; Schmid B; Winter Z; Palmisano R; Culig Z; Cronauer MV; Muschler P; Wullich B; Taubert H; Wach S
    BMC Cancer; 2024 Mar; 24(1):346. PubMed ID: 38500100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
    PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer.
    Yu J; Sun L; Hao T; Zhang B; Chen X; Li H; Zhang Z; Zhu S; Quan C; Niu Y; Shang Z
    Ann Transl Med; 2019 Dec; 7(23):729. PubMed ID: 32042745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Zadra G; Ribeiro CF; Chetta P; Ho Y; Cacciatore S; Gao X; Syamala S; Bango C; Photopoulos C; Huang Y; Tyekucheva S; Bastos DC; Tchaicha J; Lawney B; Uo T; D'Anello L; Csibi A; Kalekar R; Larimer B; Ellis L; Butler LM; Morrissey C; McGovern K; Palombella VJ; Kutok JL; Mahmood U; Bosari S; Adams J; Peluso S; Dehm SM; Plymate SR; Loda M
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):631-640. PubMed ID: 30578319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer.
    Xue L; Yu X; Zhao L; Garrett A; Wu D; Liu HY
    Mol Pharm; 2024 Nov; 21(11):5749-5760. PubMed ID: 39388218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications.
    Zhao P; Zhu Y; Cheng L; Luo J
    Asian J Urol; 2019 Jan; 6(1):109-113. PubMed ID: 30775254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.